Liz Homans - Lyell
bm-navigation: bm-t3-home-navigation
bm-pageheader: bm-t3-pageheader

Liz Homans

President

Liz Homans

Liz joins Lyell with over 30 years of strategy, product development and commercialization experience. Most recently she was at Genentech where she led US sales and marketing for the HER2 franchise (Herceptin, Perjeta and Kadcyla, a $4 billion P&L) including the launch of Perjeta in the adjuvant setting. Prior to HER2, Liz successfully led the Xolair team through two years of double-digit growth.

Before joining the US commercial organization Liz led global regulatory operations for Roche accountable for all submissions for all products in all major geographies worldwide. Prior to regulatory operations Liz led the product development team for the HER2 franchise and previously for Perjeta including lifecycle strategy development, unblinding of pivotal studies, initial filing and approval in the US and Europe and the global launch strategy. Prior to joining Genentech Liz worked at Jazz Pharmaceuticals where she led project and portfolio management.

Liz also has a decade of business strategy consulting experience with Booz Allen and Hamilton and Analysis Group (formerly Integral) working with the pharmaceutical, energy and chemical companies.

Liz received her B.A. in Economics and German from Bates College and her M.B.A. from Columbia Business School in New York City.